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Abstract
Background: The debate continues as to whether younger women who present with breast cancer have a more
aggressive form of disease and a worse prognosis. The objectives of this study were to determine the incidence of
breast cancer in women under 40 years old and to analyse the clinicopathological characteristics and outcome
compared to an older patient cohort.
Methods: Data was acquired from a review of charts and the prospectively reviewed GUH Department of Surgery
database. Included in the study were 276 women diagnosed with breast cancer under the age of forty and 2869
women over forty. For survival analysis each women less than 40 was matched with two women over forty for
both disease stage and grade.
Results: The proportion of women diagnosed with breast cancer under the age of forty in our cohort was 8.8%. In
comparison to their older counterparts, those under forty had a higher tumour grade (p = 0.044) and stage (p =
0.046), a lower incidence of lobular tumours (p < 0.001), higher estrogen receptor negativity (p < 0.001) and higher
HER2 over-expression (p = 0.002); there was no statistical difference as regards tumour size (p = 0.477). There was
no significant difference in overall survival (OS) for both groups; and factors like tumour size (p = 0.026), invasion (p
= 0.026) and histological type (p = 0.027), PR (p = 0.031) and HER2 (p = 0.002) status and treatment received were
independent predictors of OS
Conclusion: Breast cancer in younger women has distinct histopathological characteristics; however, this does not
result in a reduced survival in this population.
Background
Breast cancer accounts for approximately 23% of all
female malignancies, and its incidence is increasing,
especially in the developed countries [1]. In young
women, the incidence of the disease is low (< 17 cases
per 100,000 women or < 6% of all breast cancers among
women of any age) [2,3]; however, accumulating evi-
dence suggests that breast cancer in this age group is
more aggressive and associated with poor outcome than
in their older counterparts [4-6]
Although some reports have identified young age at
diagnosis as an adverse prognostic indicator [7], this
could be ascribed to a combination of factors, including
delayed presentation, advanced disease stage and
unfavorable tumour characteristics [8,9]. Furthermore,
the annual risk of recurrence appears to be constant
throughout life, therefore the younger the age at diagno-
sis, the higher the accumulated lifetime risk of recur-
rence [10].
The objectives of this study were to determine the
incidence of primary operable breast cancer in women
under 40 years old and to analyse the clinicopathological
characteristics and outcomes in this group of patients
compared to those over forty.
Methods
Patient cohort
Data was acquired and collated from the prospectively
reviewed Galway University hospital, Department of
Surgery breast cancer database from 1989 through to
2009. Ethical approval for this database, and therefore
any study that could arise from it, was granted by the
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Hospitals and written consent was obtained from each
of the patients before have their clinical data was
recorded and then updated. The resulting data was
further queried for cases under the age of 40 years. All
patients were treated according to local protocols and
followed three monthly for one year, 6 monthly for two
years and then annually. Male patients and women who
developed bilateral breast tumour were excluded from
the study.
Data collected included patient demographics and year
of presentation, tumour size, grade, stage, histological
type, extent of tumour invasion and lymph node invol-
vement and the presence or absence of local or distant
metastasis. Estrogen (ER), progesterone (PR) and HER-
2/neu receptor status was also noted where data was
available, as was local therapy and the use of hormonal
therapy, chemotherapy and radiotherapy.
Prior to the advent of Tamoxifen use in the late
1980s, bilateral prophylactic oopherectomy was per-
formed routinely in premenopausal women with breast
cancer. We used this group of patients to evaluate the
impact of ovarian ablation on survival of young women
with breast cancer.
The SPSS
® 17.0 software package (SPSS Inc., Chicago,
IL, USA) was used for statistical analysis. Mann-Whit-
ney U and t-tests were used, as appropriate, for compar-
ison of continuous variables and the Chi-square test was
employed for analysis of categorical variables. All tests
were two sided and a result was considered significant if
the calculated P value was < 0.05.
For survival analysis, each woman less than 40 was
matched to the two closest controls (women over forty)
for both disease stage and grade using a Malanhobis dis-
tance based on ranks, and the matching was carried out
using the Optmatch package [11,12]. Survival distribu-
tions were analyzed using the Kaplan-Meier method.
The statistical significance of differences in survival
between groups was determined by log rank. Multivari-
ate analysis was done using Cox regression, while logis-
tic regression was employed for categorical data.
Results
There were 2869 cases of breast cancer identified in the
20-year study period. The number of women diagnosed
with breast cancer under the age of forty in the database
was 276 (8.8%) (Table 1). No significant difference in
the size of the tumour at time of diagnosis was noted
between the two groups (p = 0.477). Younger women
were more likely to present with grade 3 disease (36.7%
vs. 29.3, p = 0.044) and women older than 40 years of
age were more frequently diagnosed with invasive lobu-
lar carcinoma than younger women (15.2% vs.7 . 5 5 ,p<
0.001). Although the most common presenting stages
were similar in both groups, women less than 40 years
of age were more likely to present at stage II, whereas
women older than 40 years were more likely to present
at an earlier stage (p = 0.046).
Table 1 Characteristics of breast cancer in less than 40
yrs women compared to more than 40 yrs group





Age in yrs (SD)
# < 0.001*
Mean 35.81 (3.92) 60.08 (12.22)




Median (range) 20 (1-120) 20 (1-160)
Tumour grade 0.044*
Grade 0 69 (27%) 697 (26.47%)
Grade 1 23 (9%) 262 (9.9%)
Grade 2 70 (27.3%) 912 (34.5%)
Grade 3 94 (36.7%) 774 (29.3%)
Histology Type < 0.001*
Ductal 178 (74.2%) 1768 (72.8%)
Lobular 18 (7.5%) 368 (15.2%)
Others 44 (18.3%) 291(12%)
Tumour stage 0.046*
0 17 (7.4%) 210 (9.2%)
I 66 (28.6%) 538(23.6%)
II 93 (40.3%) 850 (37.3%)
III 46 (19.9%) 477 (20.9%)
IV 9 (3.9%) 202 (8.9%)
ER status < 0.001*
Positive 123 (58.3%) 1629 (74.5%)
Negative 88 (41.7%) 559 (25.5%)
PR status 0.319
Positive 102 (70.3%) 1142 (72.5%)
Negative 43 (29.7%) 433 (27.5%)
Her-2 status 0.002*
Positive 34 (30.6%) 213 (18.6%)
Negative 77 (69.4%) 935 (81.4%)
Surgical treatment < 0.001*
Mastectomy 192 (75.9%) 1647 (61.9%)
BCS 61 (24.1%) 1012 (38.1%)
Adjuvant hormonal therapy 0.005*
Yes 184 (86.4%) 2924 (92.4%)
No 29 (13.6%) 159(7.6%)
Adjuvant chemotherapy 0.021*
Yes 109 (46.2%) 866 (38.4%)
No 127 (53.8%) 1389 (61.6%)
Adjuvant radiotherapy 0.778
Yes 135 (59.2%) 1234 (58%)
No 93 (40.8%) 892 (42%)
# Mann-Whitney u test, ER = Estrogens receptor, PR = Progesterone receptor
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There were significant differences in ER status (p <
0.001) and HER2/neu status (p = 0.002). Approximately
42% of tumours in women less than 40 years of age
were ER negative and 30.6% were HER2/neu positive;
this compared with 25.5% and 18.6% in women over 40,
respectively. There were no differences according to PR
status (p = 0.319).
Management of breast cancer in young women in our
institution
Excepting adjuvant radiotherapy, a significant trend
towards more aggressive management was noted in the
younger women cohort. They received both mastectomy
(75.9% vs.6 1 . 9 % ,p < 0.001) and adjuvant chemotherapy
(46.2% vs. 38.4%, p = 0.021) more frequently than older
women independent of disease stage. However; the dif-
ference in adjuvant chemotherapy noted between the
two groups might be due to the large number of women
> 60 years in age (only 302 of the 1278 women over 60
years old received chemotherapy). On the other hand,
women older than 40 years more frequently receive hor-
monal therapy (92.4 vs.86.4%, p=0 . 0 0 5 ). About 159
women in the more than 40 years old group (7.6%)
opted out of the hormonal therapy due to intolerable
side effects.
Survival analysis
Each of the younger breast cancer patients (n = 276)
was matched for stage and grade to two older control
patients (n = 552). Moreover, all the patients involved in
the study were of the same ethnic origin. Median (inter-
quartile range) follow-up was 194 (128-260) months for
both groups.
No significant difference in disease free survival (DFS)
was identified comparing the two groups using multi-
variate Cox regression analysis (p = 0.150). Factors like
nodal status (p = 0.012), adjuvant hormonal therapy (p
= 0.047) and adjuvant chemotherapy (p = 0.015)
emerged as independent predictors of disease recur-
rence. Furthermore, we compared the local recurrence
rates (LR) in less than 40 years group based on the sur-
gical treatment they received. No significant difference
in LR was determined comparing those who underwent
mastectomy to those who had breast conserving surgery
(BCS) using both univariate and multivariate analysis
(Figure 1). The median local recurrence-free survival for
women underwent mastectomy was 102 (76-127)
months compared to 152 (19-284) months in the BCS
group
Overall survival was calculated as the number of months
from the diagnosis of the tumour to death or last follow-
up. The median survival for women less than 40 years of
age was 243 (88-300) months while that for the older
cohort was 299 (75-329) months. No significant difference
in overall survival (OS) was noted when comparing the
two groups (Figure 2). On Cox regression analysis, tumour
size (p = 0.048), stage (p = 0.018) and PR status (p =
Log-rank 
P value = 0.455
X2 = 0.558, df = 1
At Risk:
Mastectomy            190 (0)                    120 (70)                  112 (78)                 109 (81) 
BCS                   61 (0)                      55 (16)                    52(19)                    52 (19)  
Figure 1 Local disease recurrence in women less than 40 who
were treated by mastectomy compared to breast conserving
surgery (BCS).
Log-rank
P Value = 0.578 
X2= 0.310, df = 1
At Risk:
< 40 yrs      272 (0)       226 (46)         219 (53)            217 (55)            -
> 40 yrs      540 (0)       450 (90)         441 (99)            438 (102)          -
Figure 2 Overall-survival analysis in women less than 40
compared to their older controls.
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adjustment for these variables, the OS in both groups did
not differ significantly (p = 0.587) (table 2).
In order to address the effect of bilateral prophylactic
oopherectomy, we compared the overall survival for
women less than 40 years of age who underwent oopher-
ectomy, to that in those who did not. The majority of
patients who were offered oopherectomy were stage I and
II disease (86%), and 76% of them had mastectomy as sur-
gical treatment modality. As adjuvant treatment 100% in
oopherectomy group received hormonal therapy, 36% had
radiation therapy and 24% had chemotherapy. No signifi-
cant difference in survival between the two groups was
determined using both univariate and multivariate analy-
sis. Of further interest, the group of patients who did not
receive oopherectomy lived longer than those who had
bilateral oopherectomy (mean survival of 288 months vs.
264 months (log-rank p = 0.215, X
2 =1 . 5 4 ).
Discussion
Breast cancer in patients under 40 years of age is
uncommon; however, it has generated considerable
interest because of the associated unfavorable outcome
reported in several studies [6,7,13,14]. Younger age has
been generally accepted as an independent adverse prog-
nostic indicator of survival in breast cancer [15-18].
Nevertheless, many reports suggest that the poor out-
comes associated with this age group are complicated by
several additional factors [5,13,19]. Given the lack of
routine screening programmes for women younger than
40 years, it is not surprising that women in this age
g r o u pa r em o r el i k e l yt op r e s e n tw i t hap a l p a b l em a s s
and that their tumours tends to be larger and are more
likely to have nodal involvement, than tumours detected
by screening [5,13,20].
It has been determined that underlying tumour
pathology such as higher tumour grade, nodal status
and presence of distant metastasis at diagnosis contri-
bute to the worse outcome in breast cancer in women
less than 40 years of age [4,5,21,22]. In relation to recep-
tor status, tumours in young women have been predo-
minantly reported as ER and PR negative, and have also
been shown to over-express Her2/neu [6,13,19,23,24]. In
addition; the rates of the known aggressive triple nega-
tive (PR, ER and HER2 -ve) tumour, which carries high
risk of recurrence, were reported to be higher in young
females [25]. In this study, younger women had tumours
that were distinctly different from those in older women
and were characterized by previously identified unfavor-
able biological parameters. Histopathological analysis
showed that the majority of younger women were diag-
nosed with high grade and advanced stage tumours.
Invasive ductal carcinoma was common in both groups.
Although rare in our cohort of patients, invasive lobular
carcinoma was more common in older women, a finding
similar to that published in the literature [26,27].
Furthermore, biological evaluation of breast cancer in
young women group revealed higher frequency of ER
negativity and HER2/neu overexpression. No significant
difference was identified in PR status, although it should
be noted that the majority of patients in both groups
were PR positive (70%). These findings strongly support
accumulating evidence that breast cancer in young
patients is biologically more aggressive and associated
with unfavorable prognostic markers relative to their
older counterparts.
The accumulating evidence of biologically unfavorable
breast cancer among younger women has resulted in
more aggressive treatment strategies for this patient
population. Hence, there is a very low threshold towards
more aggressive surgical treatment of breast cancer in
young females. Although BCS has been found in some
studies to be associated with higher rates of local recur-
rence after long term follow-up [28,29], numerous stu-
dies have failed to confirm the superiority of
mastectomy over breast conserving surgery (BCS) in
Table 2 Cox proportional hazards model of survival in all
patients
Variable B SE Wald df Sig. Exp(B)
Age at diagnosis .019 .012 2.661 1 .103 1.019
Category -.566 .355 2.539 1 .111 .568
Tumour size .022 .007 8.981 1 .003* 1.022
Tumour grade .097 .095 1.027 1 .311 1.101
Histological type -.062 .105 .353 1 .552 .939
Tumour invasion .009 .159 .003 1 .956 1.009
Nodal status .131 .089 2.165 1 .141 1.140
Distant metastasis .107 .272 .154 1 .695 1.113
ER receptors status .039 .036 1.161 1 .281 1.040
PR receptors status .119 .051 5.351 1 .021* 1.126
HER2 status -.090 .056 2.591 1 .107 .914
Hormonal therapy -.264 .389 .462 1 .497 .768
Chemotherapy -.007 .079 .008 1 .927 .993
Radiotherapy -.003 .010 .071 1 .790 .997
Surgical treatment .011 .209 .003 1 .957 1.011
The output of this analysis includes the unstandardized regression coefficient
(B), the standard error of B and its Wald test significance value, the degrees of
freedom and the significance value of the coefficient. If the significance value
for the coefficient is more than 0 050, then the co-variate effect cannot be
assumed to be different from 0. The predicted change in the hazard per unit
increase in the co-variate is Exp (B); if the value is less than 1, then the
direction of the effect is towards reducing the hazard rate. To be considered
to have a significant effect on the hazard rate, the 95 per cent confidence
interval for the Exp (B) should not include 1.
Category = less than 40 yrs group vs. more than 40 yrs group
(*) = significant values.
df = degree of freedom
B = unstandardized regression coefficient;
Exp (B) = predicted change in the hazard per unit increase in the co-variate
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those is a recent report by Livi et al., who analysed the
breast cancer outcome in 346 young females and found
no significant role of surgical treatment (mastectomy vs.
BCS) as predictor of local recurrence [22]. In this study,
and in keeping with literature, although the majority of
our young patients underwent mastectomy, we found no
significant difference in local recurrence-free survival
between the mastectomy and BCS groups.
The role of postoperative radiotherapy in reducing
breast cancer local recurrence has been confirmed in
many studies [30-34]. However; there is conflicting evi-
dence in translating its role in controlling local recur-
rence into breast cancer mortality reduction
[30,33,35,36]. Significant survival improvements have
been reported in subgroup analyses of patients with
favorable prognostic indicators like: grade I disease, less
than 3 positive lymph nodes, tumours less than 2 cm
and hormone receptors positive disease, but not in high
risk groups [33,35,37-39]. Adjuvant chemotherapy has
been shown to benefit young patients with approxi-
mately 37% reduction in recurrence rates and a 27%
reduction in death rates [40,41]. With both single-agent
chemotherapy and polychemotherapy, there is trend
towards greater benefits among younger women, but
both for recurrence and for mortality the age-standar-
dized effect of single-agent regimens were significantly
less favorable than those of the polychemotherapy regi-
mens [42]. Regarding chemotherapeutic agents, it has
been widely accepted that anthracyclines and taxanes
are the most effective agents in adjuvant settings of
breast cancer management in young females. A meta-
analysis by the early breast cancer trialists’ collaboration
group (EBCTCG) showed that 6 months of anthracy-
cline-based polychemotherapy reduces the annual breast
cancer death by about 38% for women younger that 50
years of age at diagnosis [42].
Hormonal therapy effect had been considered of sec-
ondary importance in young females with breast cancer.
However; it has become common current practice to
follow adjuvant chemotherapy in receptor positive
young women. This practice is based on the evidences
provided by recent trials [42-46]. Hormonal therapy
value in premenopausal women has been defined
recently in a meta-analysis of randamised trials which
showed that combination of chemotherapy with 5 years
Tamoxifen in ER positive breast cancer reduce risk of
death by 57% [42]. In addition, the intermediate results
of the international breast cancer study group trial con-
firmed that Tamoxifen significantly improve outcome in
premenopausal women with hormone receptors positive
disease [44].
Therefore, in our cohort of patients, those less than 40
years of age were managed aggressively independent of
the disease stage. Further elucidation of tumour charac-
teristics such as HER2neu status has given adjuvant
therapists the opportunity to tailor systemic treatment
and clearly the younger patients are more suited to this
treatment based on our and others findings
Previous reports comparing survival between women
less than and greater than 40, with breast cancer have
returned inconsistent results. Both Kollias et al. and Yil-
d i r i me ta l .f o u n dd e c r e a s e dD F Sa n dO Si ny o u n g e r
patients [17,18]. However; other studies have demon-
strated that, young age in its own is not an adverse
prognostic factor [13,47]. The small number of patients,
study design and the employment of different statistical
methods might explain these variations. Moreover, only
a few studies have assessed the prognostic indicators in
order to confirm whether the poorer outcome in
younger women could be related to the biological char-
acteristics of their tumours. By controlling for confoun-
ders and employing multivariate analysis methods, we
have been unable to identify significant difference in
both DFS and OS between the two groups of patients.
Consistent with McAree et al [19], we identified PR
receptor positivity as a predictor of survival in younger
women with breast cancer. In additions; other variables
l i k et u m o u rs i z ea n ds t a g ew e r es h o w nt oi n f l u e n c eO S
while nodal status and adjuvant chemoendocrine ther-
apy predicted DFS in women less than 40 by multivari-
ate analysis. We have failed to identify any benefit of
ovarian ablation in improving OS in younger women.
Interestingly, the group of patients who received bilat-
eral prophylactic oopherectomy had poorer OS than
those who did not. This finding could be explained by
the fact that most of our patients had adjuvant chemo-
endocrine therapy. EBCTCG overviews have shown
that, although ovarian ablation is associated with
improved survival for premenopausal women both on
recurrence and on breast cancer mortality, the effect of
ovarian treatment appear to be smaller in the trials
where both groups got chemotherapy [42]. In addition,
they reported that more breast cancer related deaths
were noted in the trials of ovarian ablation in the pre-
sence of chemotherapy than in the trials of ablation in
the absence of chemotherapy [48-50]. This could par-
tially be explained by the toxic effect of chemotherapy
on the ovary, limiting the benefits of other ovarian
treatments.
Conclusions
This study has demonstrated that women less than 40
years of age present with higher grade and poorly differ-
entiated tumours. Moreover; younger women had
t u m o u r st h a tw e r em o r el i k e l yt ob eE Rn e g a t i v ea n d
HER2/neu receptor over-expressed. However; we have
shown no difference in both disease-free survival and
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women over 40 years of age.
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